Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity

Takayoshi Suzuki, Hiroki Ozasa, Yukihiro Itoh, Peng Zhan, Hideyuki Sawada, Koshiki Mino, Louise Walport, Rei Ohkubo, Akane Kawamura, Masato Yonezawa, Yuichi Tsukada, Anthony Tumber, Hidehiko Nakagawa, Makoto Hasegawa, Ryuzo Sasaki, Tamio Mizukami, Christopher J. Schofield, Naoki Miyata

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Histone Nε-methyl lysine demethylases KDM2/7 have been identified as potential targets for cancer therapies. On the basis of the crystal structure of KDM7B, we designed and prepared a series of hydroxamate analogues bearing an alkyl chain. Enzyme assays revealed that compound 9 potently inhibits KDM2A, KDM7A, and KDM7B, with IC50s of 6.8, 0.2, and 1.2 μM, respectively. While inhibitors of KDM4s did not show any effect on cancer cells tested, the KDM2/7-subfamily inhibitor 9 exerted antiproliferative activity, indicating the potential for KDM2/7 inhibitors as anticancer agents.

Original languageEnglish
Pages (from-to)7222-7231
Number of pages10
JournalJournal of Medicinal Chemistry
Volume56
Issue number18
DOIs
Publication statusPublished - Sep 26 2013

Fingerprint

Histone Demethylases
Enzyme Assays
Antineoplastic Agents
Histones
Lysine
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery

Cite this

Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity. / Suzuki, Takayoshi; Ozasa, Hiroki; Itoh, Yukihiro; Zhan, Peng; Sawada, Hideyuki; Mino, Koshiki; Walport, Louise; Ohkubo, Rei; Kawamura, Akane; Yonezawa, Masato; Tsukada, Yuichi; Tumber, Anthony; Nakagawa, Hidehiko; Hasegawa, Makoto; Sasaki, Ryuzo; Mizukami, Tamio; Schofield, Christopher J.; Miyata, Naoki.

In: Journal of Medicinal Chemistry, Vol. 56, No. 18, 26.09.2013, p. 7222-7231.

Research output: Contribution to journalArticle

Suzuki, T, Ozasa, H, Itoh, Y, Zhan, P, Sawada, H, Mino, K, Walport, L, Ohkubo, R, Kawamura, A, Yonezawa, M, Tsukada, Y, Tumber, A, Nakagawa, H, Hasegawa, M, Sasaki, R, Mizukami, T, Schofield, CJ & Miyata, N 2013, 'Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity', Journal of Medicinal Chemistry, vol. 56, no. 18, pp. 7222-7231. https://doi.org/10.1021/jm400624b
Suzuki, Takayoshi ; Ozasa, Hiroki ; Itoh, Yukihiro ; Zhan, Peng ; Sawada, Hideyuki ; Mino, Koshiki ; Walport, Louise ; Ohkubo, Rei ; Kawamura, Akane ; Yonezawa, Masato ; Tsukada, Yuichi ; Tumber, Anthony ; Nakagawa, Hidehiko ; Hasegawa, Makoto ; Sasaki, Ryuzo ; Mizukami, Tamio ; Schofield, Christopher J. ; Miyata, Naoki. / Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity. In: Journal of Medicinal Chemistry. 2013 ; Vol. 56, No. 18. pp. 7222-7231.
@article{d4e5424b356349998a71468e2de45b9b,
title = "Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity",
abstract = "Histone Nε-methyl lysine demethylases KDM2/7 have been identified as potential targets for cancer therapies. On the basis of the crystal structure of KDM7B, we designed and prepared a series of hydroxamate analogues bearing an alkyl chain. Enzyme assays revealed that compound 9 potently inhibits KDM2A, KDM7A, and KDM7B, with IC50s of 6.8, 0.2, and 1.2 μM, respectively. While inhibitors of KDM4s did not show any effect on cancer cells tested, the KDM2/7-subfamily inhibitor 9 exerted antiproliferative activity, indicating the potential for KDM2/7 inhibitors as anticancer agents.",
author = "Takayoshi Suzuki and Hiroki Ozasa and Yukihiro Itoh and Peng Zhan and Hideyuki Sawada and Koshiki Mino and Louise Walport and Rei Ohkubo and Akane Kawamura and Masato Yonezawa and Yuichi Tsukada and Anthony Tumber and Hidehiko Nakagawa and Makoto Hasegawa and Ryuzo Sasaki and Tamio Mizukami and Schofield, {Christopher J.} and Naoki Miyata",
year = "2013",
month = "9",
day = "26",
doi = "10.1021/jm400624b",
language = "English",
volume = "56",
pages = "7222--7231",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "18",

}

TY - JOUR

T1 - Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity

AU - Suzuki, Takayoshi

AU - Ozasa, Hiroki

AU - Itoh, Yukihiro

AU - Zhan, Peng

AU - Sawada, Hideyuki

AU - Mino, Koshiki

AU - Walport, Louise

AU - Ohkubo, Rei

AU - Kawamura, Akane

AU - Yonezawa, Masato

AU - Tsukada, Yuichi

AU - Tumber, Anthony

AU - Nakagawa, Hidehiko

AU - Hasegawa, Makoto

AU - Sasaki, Ryuzo

AU - Mizukami, Tamio

AU - Schofield, Christopher J.

AU - Miyata, Naoki

PY - 2013/9/26

Y1 - 2013/9/26

N2 - Histone Nε-methyl lysine demethylases KDM2/7 have been identified as potential targets for cancer therapies. On the basis of the crystal structure of KDM7B, we designed and prepared a series of hydroxamate analogues bearing an alkyl chain. Enzyme assays revealed that compound 9 potently inhibits KDM2A, KDM7A, and KDM7B, with IC50s of 6.8, 0.2, and 1.2 μM, respectively. While inhibitors of KDM4s did not show any effect on cancer cells tested, the KDM2/7-subfamily inhibitor 9 exerted antiproliferative activity, indicating the potential for KDM2/7 inhibitors as anticancer agents.

AB - Histone Nε-methyl lysine demethylases KDM2/7 have been identified as potential targets for cancer therapies. On the basis of the crystal structure of KDM7B, we designed and prepared a series of hydroxamate analogues bearing an alkyl chain. Enzyme assays revealed that compound 9 potently inhibits KDM2A, KDM7A, and KDM7B, with IC50s of 6.8, 0.2, and 1.2 μM, respectively. While inhibitors of KDM4s did not show any effect on cancer cells tested, the KDM2/7-subfamily inhibitor 9 exerted antiproliferative activity, indicating the potential for KDM2/7 inhibitors as anticancer agents.

UR - http://www.scopus.com/inward/record.url?scp=84884997299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884997299&partnerID=8YFLogxK

U2 - 10.1021/jm400624b

DO - 10.1021/jm400624b

M3 - Article

VL - 56

SP - 7222

EP - 7231

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 18

ER -